Harvard University collaborates with Merck to develop novel cancer therapeutics
Harvard University has entered into an exclusive license and research collaboration agreement with Merck, known as MSD outside the United States and Canada, to further the development of small-molecule therapeutics for leukemia and other cancers. The novel compounds, developed in the laboratory of Harvard scientist Matthew Shair, Ph.D., offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription.
Click on this link for more information.
